Log In or Register to Join The Conversation!
Viewing 0 reply threads
  • Author
    Posts
    • #20602
      Ed Tobias
      Keymaster

      NICE is the government agency that recommends which drugs should be provided to National Health Service patients in England and Wales. It’s just said no to Zeposia (ozanimod), claiming it’s not as cost-effective as Avonex (inteferon beta1-a) to treat MS.

      Have you considered switching from Avonex to Zeposia? Should cost-effectiveness ever be a factor in the ability to have a medication prescribed?

Viewing 0 reply threads
  • You must be logged in to reply to this topic.
Copyright © 2017-2021 All rights reserved.

©2021 KLEO Template a premium and multipurpose theme from Seventh Queen

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending
or

Log in with your credentials

or    

Forgot your details?

or

Create Account